On the evening of April 23, Minsheng Health (301507.SZ) released 2023 reports.In 2023, Minsheng Health realized operating income of 58.1733 million yuan, an increase of 6.33%year -on -year; net profit attributable to the mother was 85.638 million yuan, an increase of 8.38%year -on -year; the non -net profit was 79.187 million yuan, a year -on -year increase of 12.61%.Minsheng Health also released a full -year profit distribution plan in 2023. It is intended to send a cash dividend of 1.00 yuan (tax) per 10 shares to all shareholders. It is expected that the total cash amount will be 35.6554 million yuan (including tax).
Minsheng Health stated that in 2023, the company actively welcomed opportunities and challenges, comprehensively promoted the improvement of operating quality, continued to use vitamin and mineral supplements series products as the core of business development, continuously optimized product structure, strengthened channels for channels, enhanced market influence, operating performance performanceRealize steady growth.
Build more brand matrices in the area
It is reported that Minsheng Health focuses on the field of vitamins and mineral supplements. It is a high -tech enterprise that integrates vitamins and minerals and mining materials and health foods.In 1985, it was developed and launched, creating a precedent for the domestic mining industry.
Today, “21 Jinwei” has developed into a leading brand in the domestic maintenance field. The brand awareness, reputation and influence have been continuously improved. In 20232023 Chinese Brand Fortune 500 “list.During the reporting period, multi -dimensional element films (21) achieved revenue of 476 million yuan, an increase of 8.47%year -on -year.
On the basis of the main brand “21 Golden Wei”, the health of people’s livelihood and actively explore, expand the audience as a “1 belt” manner, broaden the industrial boundary, build a brand matrix, and form a brand complementarity.
Through the influence of the main brand 21 Jinwei Multidimensional tablets, people’s livelihood health has expanded the non -prescribed drug matrix of calcium tablets, vitamin C, and vitamin E.In addition, Minsheng Health has also created a precise maintenance food health food matrix with segmented people, segmented age, and subdivision functions.For example, the sub -brand “21 Jinwei Po number+” and the child brand “Xiao Jinwei”, which focuses on children’s nutrition.In 2023, the company’s other Vitamin OTC products achieved operating income of RMB 1.16 million, and a variety of vitamin mineral slices of health foods and food achieved revenue of 77 million yuan, an increase of 19.71%year -on -year.
During the reporting period, Minsheng Health continued to diversify online and offline channels to enhance brand terminal thrust.While maintaining the steady growth of traditional channels such as JD, Ali, and Pinduoduo, new e -commerce platforms such as Douyin, Quick Hand, etc. are added, and they cover a wider range of user groups.At the same time, Minsheng Health has differentiated product positioning according to the characteristics of different online stores and audiences, highlighting the uniqueness and characteristics of each shop, formulating integration of online marketing strategies, enhancing brand exposure and attractiveness, and through newMarketing methods drive the growth of new business sales.
Actively explore multiple tracks
In recent years, my country has vigorously advocated and continued to promote the “healthy China” strategy, and has promulgated a number of policies successively to promote the high -quality development of the industry and also put forward higher requirements for enterprises’ innovation capabilities.
After years of deep cultivation, Minsheng Health has formed a set of product formulas such as the proportion technology, trace nutrient mixed uniformity control methods, vitamin and mineral tablets, and trace vitamin detection methods.The core technical system of the production process system, quality control and inspection system, and continuously improve, optimize, iterates on this basis.
In terms of new product research and development, Minsheng Health has established a multi -department cooperation R & D mechanism.Through R & D and innovation, vigorously promoted the research and development of new products. In 2023, the investment in R & D is 29.5565 million yuan, accounting for 5.08%of the company’s operating income.In the non -prescription medicine, health food, probiotics and other sectors, the R & D team has new projects for research.Among them, 3 items of OTC drug registration are completed, 1 drug supplement, 13 new health foods, and 9 newly established functional foods.
During the reporting period, 3 new invention patents and 2 utility model patents were added in the reporting period.As of December 31, 2023, the company and subsidiaries had 61 authorized patents, 9 drug registration approval, and 51 health food approval.
In addition to the continuous investment in the field of vitamin and probiotics, Minsheng Health said that it will also explore new tracks such as raw hair, intestinal health, sleep health, and proprietary patent medicine tonic to seek new product pipelines.In the future, people’s livelihood health will always focus on the field of vitamins and mineral supplements necessary for the human body. It is guided by innovating the concept of innovation and healthy development.Leading life and health enterprises.
